drugset / Trial / NCT01766219
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
Phase 1/2
Completed
17 enrolled
Wake Forest University Health Sciences
National Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This pilot clinical trial studies 6,8-bis(benzylthio)octanoic acid in treating patients with advanced or metastatic cholangiocarcinoma that cannot be removed by surgery. 6,8-Bis(benzylthio)octanoic acid may stop the growth of cholangiocarcinoma by blocking blood flow to the tumor
Timeline
- Start
- 2013-05
- Primary completion
- 2018-04
- Completion
- 2018-05-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPI-613 | Small molecule | 2300 mg/m2 | Intravenous |
| Subject | CPI-613 | Small molecule | 3000 mg/m2 | Intravenous |